Iota-Carrageenan Inhibits Replication of the SARS-CoV-2 Variants of Concern Omicron BA.1, BA.2 and BA.5
暂无分享,去创建一个
U. Schubert | M. Schindler | P. Rauch | A. Ensser | A. Herrmann | Martina Morokutti-Kurz | Philipp Graf | A. Grassauer | Eva Prieschl-Grassauer | A. Cordsmeier | Maria Fröba | M. Große | Janina Auth | Christian Setz | Benedikt Engel
[1] G. Hardiman,et al. In-Silico Approaches for the Screening and Discovery of Broad-Spectrum Marine Natural Product Antiviral Agents Against Coronaviruses , 2023, Infection and drug resistance.
[2] Kristen D. Popowski,et al. An inhaled bioadhesive hydrogel to shield non-human primates from SARS-CoV-2 infection , 2023, Nature Materials.
[3] U. Schubert,et al. European Black Elderberry Fruit Extract Inhibits Replication of SARS-CoV-2 In Vitro , 2023, Nutraceuticals.
[4] R. Webby,et al. Characterization of SARS-CoV-2 Omicron BA.4 and BA.5 isolates in rodents , 2022, Nature.
[5] H. Jäck,et al. Omicron sublineage BQ.1.1 resistance to monoclonal antibodies , 2022, The Lancet Infectious Diseases.
[6] K. Mølbak,et al. Household transmission of SARS-CoV-2 Omicron variant of concern subvariants BA.1 and BA.2 in Denmark , 2022, Nature Communications.
[7] W. Marasco,et al. Immune Evasion of SARS-CoV-2 Omicron Subvariants , 2022, Vaccines.
[8] Fei Shao,et al. Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies , 2021, bioRxiv.
[9] S. Karim,et al. Omicron SARS-CoV-2 variant: a new chapter in the COVID-19 pandemic , 2021, The Lancet.
[10] J. Münch,et al. Iota-Carrageenan Inhibits Replication of SARS-CoV-2 and the Respective Variants of Concern Alpha, Beta, Gamma and Delta , 2021, International journal of molecular sciences.
[11] G. Luo,et al. Omicron variant (B.1.1.529) of SARS‐CoV‐2, a global urgent public health alert! , 2021, Journal of medical virology.
[12] R. Giugliano,et al. Efficacy of a Nasal Spray Containing Iota-Carrageenan in the Postexposure Prophylaxis of COVID-19 in Hospital Personnel Dedicated to Patients Care with COVID-19 Disease , 2021, International journal of general medicine.
[13] Anoop Misra,et al. Molnupiravir in COVID-19: A systematic review of literature , 2021, Diabetes & Metabolic Syndrome: Clinical Research & Reviews.
[14] U. Schubert,et al. Lectin from Triticum vulgaris (WGA) Inhibits Infection with SARS-CoV-2 and Its Variants of Concern Alpha and Beta , 2021, International journal of molecular sciences.
[15] M. Savli,et al. The Saliva of Probands Sucking an Iota-Carrageenan Containing Lozenge Inhibits Viral Binding and Replication of the Most Predominant Common Cold Viruses and SARS-CoV-2 , 2021, International journal of general medicine.
[16] D. G. Goroso,et al. Intensive Treatment With Ivermectin and Iota-Carrageenan as Pre-exposure Prophylaxis for COVID-19 in Health Care Workers From Tucuman, Argentina , 2021, American journal of therapeutics.
[17] M. Rateb,et al. Marine Sulfated Polysaccharides as Promising Antiviral Agents: A Comprehensive Report and Modeling Study Focusing on SARS CoV-2 , 2021, Marine drugs.
[18] S. Singh,et al. SARS-CoV-2 Spike Mutations, L452R, T478K, E484Q and P681R, in the Second Wave of COVID-19 in Maharashtra, India , 2021, Microorganisms.
[19] A. Frediansyah. The antiviral activity of iota-, kappa-, and lambda-carrageenan against COVID-19: A critical review , 2021, Clinical Epidemiology and Global Health.
[20] William T. Harvey,et al. Recurrent emergence of SARS-CoV-2 spike deletion H69/V70 and its role in the Alpha variant B.1.1.7 , 2021, Cell Reports.
[21] U. Schubert,et al. Quinine Inhibits Infection of Human Cell Lines with SARS-CoV-2 , 2021, Viruses.
[22] William T. Harvey,et al. Author Correction: Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies , 2021, Nature.
[23] Sergei L. Kosakovsky Pond,et al. Detection of a SARS-CoV-2 variant of concern in South Africa , 2021, Nature.
[24] L. Morris,et al. SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma , 2021, Nature Medicine.
[25] Jason A Hendry,et al. Detection of B.1.351 SARS-CoV-2 Variant Strain — Zambia, December 2020 , 2021, MMWR. Morbidity and mortality weekly report.
[26] C. Creech,et al. SARS-CoV-2 Vaccines. , 2021, JAMA.
[27] U. Schubert,et al. Iota-carrageenan neutralizes SARS-CoV-2 and inhibits viral replication in vitro , 2021, PloS one.
[28] J. Münch,et al. Carrageenan-containing over-the-counter nasal and oral sprays inhibit SARS-CoV-2 infection of airway epithelial cultures , 2021, American journal of physiology. Lung cellular and molecular physiology.
[29] M. Biggerstaff,et al. Emergence of SARS-CoV-2 B.1.1.7 Lineage — United States, December 29, 2020–January 12, 2021 , 2021, MMWR. Morbidity and mortality weekly report.
[30] Myoung Kyu Lee,et al. Antiviral activity of lambda-carrageenan against influenza viruses and severe acute respiratory syndrome coronavirus 2 , 2021, Scientific reports.
[31] R. Hammal,et al. Sulphated polysaccharides from seaweeds as potential entry inhibitors and vaccine adjuvants against SARS-CoV-2 RBD spike protein: a computational approach , 2021, Journal of Taibah University for Science.
[32] H. Hemilä,et al. Carrageenan nasal spray may double the rate of recovery from coronavirus and influenza virus infections: Re‐analysis of randomized trial data , 2020, Pharmacology research & perspectives.
[33] S. Rowland-Jones,et al. Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus , 2020, Cell.
[34] R. Eccles. Iota-Carrageenan as an Antiviral Treatment for the Common Cold , 2020, The Open Virology Journal.
[35] K. Walsh,et al. Natural product-derived phytochemicals as potential agents against coronaviruses: A review , 2020, Virus Research.
[36] Paul J. Hanson,et al. Gene expression and in situ protein profiling of candidate SARS-CoV-2 receptors in human airway epithelial cells and lung tissue , 2020, European Respiratory Journal.
[37] Victor M Corman,et al. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR , 2020, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.
[38] P. Galtier,et al. Re‐evaluation of carrageenan (E 407) and processed Eucheuma seaweed (E 407a) as food additives , 2018, EFSA journal. European Food Safety Authority.
[39] Martina Morokutti-Kurz,et al. Amylmetacresol/2,4-dichlorobenzyl alcohol, hexylresorcinol, or carrageenan lozenges as active treatments for sore throat , 2017, International journal of general medicine.
[40] S. Johnston,et al. Efficacy and safety of iota-carrageenan nasal spray versus placebo in early treatment of the common cold in adults: the ICICC trial , 2015, Respiratory Research.
[41] E. Martinelli,et al. Griffithsin and Carrageenan Combination To Target Herpes Simplex Virus 2 and Human Papillomavirus , 2015, Antimicrobial Agents and Chemotherapy.
[42] Zhi-Yao He,et al. Antitumor and Adjuvant Activity of λ-carrageenan by Stimulating Immune Response in Cancer Immunotherapy , 2015, Scientific Reports.
[43] S. Nakowitsch,et al. The Intranasal Application of Zanamivir and Carrageenan Is Synergistically Active against Influenza A Virus in the Murine Model , 2015, PloS one.
[44] Yitao Wang,et al. Review for carrageenan-based pharmaceutical biomaterials: favourable physical features versus adverse biological effects. , 2015, Carbohydrate polymers.
[45] A. Bodenteich,et al. Non-Clinical Safety Evaluation of Intranasal Iota-Carrageenan , 2015, PloS one.
[46] T. Lion,et al. Carrageenan nasal spray in virus confirmed common cold: individual patient data analysis of two randomized controlled trials , 2014, Multidisciplinary Respiratory Medicine.
[47] M. Weiner. Food additive carrageenan: Part II: A critical review of carrageenan in vivo safety studies , 2014, Critical reviews in toxicology.
[48] T. Lion,et al. Efficacy of a Carrageenan nasal spray in patients with common cold: a randomized controlled trial , 2013, Respiratory Research.
[49] T. Lion,et al. Lessons learned from a double-blind randomised placebo-controlled study with a iota-carrageenan nasal spray as medical device in children with acute symptoms of common cold , 2012, BMC Complementary and Alternative Medicine.
[50] M. Beer,et al. Iota-Carrageenan Is a Potent Inhibitor of Influenza A Virus Infection , 2010, PloS one.
[51] C. Meier,et al. Efficacy and safety of an antiviral Iota-Carrageenan nasal spray: a randomized, double-blind, placebo-controlled exploratory study in volunteers with early symptoms of the common cold , 2010, Respiratory research.
[52] Daniel Fábio Kawano,et al. Carrageenans: biological properties, chemical modifications and structural analysis - a review. , 2009 .
[53] C. Meier,et al. Iota-Carrageenan is a potent inhibitor of rhinovirus infection , 2008, Virology Journal.
[54] K. Kitazato,et al. Viral infectious disease and natural products with antiviral activity. , 2007, Drug discoveries & therapeutics.
[55] Ning Li,et al. Immunomodulation and antitumor activity of κ-carrageenan oligosaccharides , 2006 .
[56] Changhai Wang,et al. Effect of low molecular λ-carrageenan from Chondrus ocellatus on antitumor H-22 activity of 5-Fu , 2006 .
[57] I. Capron,et al. In-vitro gastric stability of carrageenan , 1996 .
[58] L. Reed,et al. A SIMPLE METHOD OF ESTIMATING FIFTY PER CENT ENDPOINTS , 1938 .
[59] S. Austin,et al. Determination of the low molecular weight fraction of food-grade carrageenans. , 2008, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
[60] O. Smidsrod,et al. Analysis of the conformational properties of ?- and ?-carrageenan by size-exclusion chromatography combined with low-angle laser light scattering , 1999 .
[61] J. Crance,et al. Antiviral activity of carrageenan on hepatitis A virus replication in cell culture. , 1991, Research in virology.
[62] W. Marrs,et al. Characterisation of carrageenans by high-performance size-exclusion chromatography using a LiChrospher 1000 DIOL column. , 1987, Journal of chromatography.